Panelists:
Chad Brenner, PhD
Associate Professor of Otolaryngology - Head & Neck Surgery
University of Michigan
- Time:
Human papillomavirus (HPV)-associated cancers, which target the skin and mucus membranes, account for a growing proportion of malignancies worldwide, particularly in the head and neck region. Minimally invasive technologies like circulating tumor DNA (ctDNA) testing are emerging as promising tools for supporting diagnosis, monitoring treatment response, and detecting recurrence. Advances in assay development and PCR platforms are defining how HPV ctDNA tests can be integrated into clinical workflows.
In this IPM webinar, Chad Brenner, PhD, will describe the development, validation, and clinical implementation of MyHPVscore™, a Droplet Digital PCR-based circulating tumor HPV DNA assay performed on the Bio-Rad QX200 platform. He will highlight the role of HPV ctDNA testing in patients with HPV-positive cancers, including applications for diagnosis support, recurrence surveillance, and clinical monitoring. He will also emphasize the operational experience of establishing and running the assay in a CLIA laboratory, including workflow optimization, assay performance, sample processing, quality control, and integration into clinical and translational research programs. Lastly, his talk will go over ongoing efforts to expand HPV ctDNA testing applications, including future opportunities for broader clinical deployment.
A live Q&A session followed the presentation offering a chance to pose questions to our expert panelist.
Produced with support from:







